IMR Press / CEOG / Volume 45 / Issue 4 / DOI: 10.12891/ceog4046.2018

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

The importance of angiogenic and antiangiogenic biomarkers in pathogenesis and early diagnosis of preeclampsia
Show Less
1 Faculty of Medicine, Vilnius University, Vilnius, Lithuania
2 Faculty of Medicine, Clinic of internal medicine, oncology and family medicine;Vilnius University, Vilnius, Lithuania
3 Vilnius University Hospital Santariskiu Clinics, Vilnius, Lithuania
4 Faculty of Medicine, clinic of obstetric and gynaecology, Vilnius University, Vilnius, Lithuania
Clin. Exp. Obstet. Gynecol. 2018, 45(4), 485–492;
Published: 10 August 2018

The early diagnosis of preeclampsia (PE) remains one of the great medical problems worldwide. PE is a multisystemic disorder and the etiology is still unclear. The equilibrium between anti-angionenic and angiogenic factors is essential in the PE pathogenesis. In this review, the authors highlight the role of key circulating anti-angionenic and antiangiogenic factors as pathogenic biomarkers and as well as early diagnostic biomarkers for PE. They analyzed the main anti-angiogenic factors: soluble FMS–like tyrosine kinase (sFlt-1), soluble endoglin (sEng), and the angiogenic factors – vascular endothelial growth factor (VEGF) and placental growth factor (P1GF). An accurate algorithm for diagnosing PE using only biomarkers is still absent.
Anti-angiogenic factors
Angiogenic factors
Back to top